FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2518330493> ?p ?o ?g. }

• W2518330493 endingPage "59" @default.
• W2518330493 startingPage "50" @default.
• W2518330493 abstract "<b><i>Background:</i></b> Thrombolysis is the only approved therapy for acute stroke. However, life-threatening complications such as intracerebral hemorrhage (ICH) can develop after intravenous administration of tissue plasminogen activator (tPA). Both infection and thrombolysis during cerebral ischemia disrupt the blood-brain barrier (BBB). tPA can induce matrix metalloproteinase-9 (MMP-9), which is known to be involved in BBB disruption. However, it has still not been investigated whether preexisting influenza virus infection during thrombolysis after acute stroke affects systemic levels of MMP-9 and its inhibitor TIMP-1 and whether increased systemic MMP-9 levels affect ICH. This study aimed to investigate the influence of influenza virus infection on plasma levels of MMP-9 and TIMP-1 after thrombolysis in acute stroke, and to determine whether the infection correlates with intracerebral bleeding. <b><i>Methods:</i></b> C57BL/6 mice were infected by administering 1 × 10⁵ plaque-forming units of human influenza (H1N1) virus intranasally. After 3 days of infection the middle cerebral artery was occluded for 45 min and then reperfused. Intravenous tPA (10 mg/kg) treatment was started 10 min after stroke onset. Twenty-four hours after stroke onset, mice were deeply anesthetized with ketamine, venous blood was drawn from the caval vein and centrifuged at 2,000 rpm, and the supernatant was collected and frozen at -80°C. Plasma levels of MMP-9 and TIMP-1 were quantified by using ELISA. <b><i>Results:</i></b> After stroke, plasma MMP-9 was significantly increased in mice with a concomitant influenza infection that were treated with tPA (9.99 ± 0.62 ng/ml, n = 7) as compared to noninfected control mice that were treated with tPA (4.74 ± 0.48 ng/ml, n = 8). Moreover, plasma levels of TIMP-1, an inhibitor of MMP-9, were also significantly increased in mice treated with tPA after concomitant infection and stroke (42.17 ± 7.02 ng/ml, n = 7) as compared to noninfected control mice that were treated with tPA after stroke (20.22 ± 2.12 ng/ml, n = 8). MMP-9 values significantly correlated with intracerebral hemoglobin levels in animals treated with tPA after stroke (p = 0.028, r = 0.76, n = 8) and after concomitant stroke and infection (p = 0.039, r = 0.78, n = 7). <b><i>Conclusion:</i></b> Preexisting influenza A virus infection led to increased plasma MMP-9 and TIMP-1 levels in mice undergoing thrombolysis after induced stroke. MMP-9 levels closely correlated with intracerebral bleeding after thrombolysis during concomitant infection and stroke. Thus, our data indicate that thrombolysis may be dangerous during influenza infection. MMP-9 inhibitors might be considered to reduce the side effects of thrombolysis during concomitant infection and stroke." @default.
• W2518330493 created "2016-09-16" @default.
• W2518330493 creator A5009423317 @default.
• W2518330493 creator A5048321390 @default.
• W2518330493 creator A5058408501 @default.
• W2518330493 date "2016-08-25" @default.
• W2518330493 modified "2023-09-23" @default.
• W2518330493 title "Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection" @default.
• W2518330493 cites W1689288238 @default.
• W2518330493 cites W1966224676 @default.
• W2518330493 cites W1969909530 @default.
• W2518330493 cites W1973077882 @default.
• W2518330493 cites W1985131865 @default.
• W2518330493 cites W1992218027 @default.
• W2518330493 cites W1997064745 @default.
• W2518330493 cites W2005279748 @default.
• W2518330493 cites W2018782821 @default.
• W2518330493 cites W2024276472 @default.
• W2518330493 cites W2024661673 @default.
• W2518330493 cites W2039176792 @default.
• W2518330493 cites W2054441747 @default.
• W2518330493 cites W2065247090 @default.
• W2518330493 cites W2066700182 @default.
• W2518330493 cites W2070320506 @default.
• W2518330493 cites W2104648020 @default.
• W2518330493 cites W2116222748 @default.
• W2518330493 cites W2119485597 @default.
• W2518330493 cites W2122866927 @default.
• W2518330493 cites W2123648780 @default.
• W2518330493 cites W2124296416 @default.
• W2518330493 cites W2127272421 @default.
• W2518330493 cites W2133045741 @default.
• W2518330493 cites W2133514192 @default.
• W2518330493 cites W2143167573 @default.
• W2518330493 cites W2150658610 @default.
• W2518330493 doi "https://doi.org/10.1159/000447750" @default.
• W2518330493 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5040893" @default.
• W2518330493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27560521" @default.
• W2518330493 hasPublicationYear "2016" @default.
• W2518330493 type Work @default.
• W2518330493 sameAs 2518330493 @default.
• W2518330493 citedByCount "12" @default.
• W2518330493 countsByYear W25183304932018 @default.
• W2518330493 countsByYear W25183304932019 @default.
• W2518330493 countsByYear W25183304932020 @default.
• W2518330493 countsByYear W25183304932021 @default.
• W2518330493 countsByYear W25183304932022 @default.
• W2518330493 crossrefType "journal-article" @default.
• W2518330493 hasAuthorship W2518330493A5009423317 @default.
• W2518330493 hasAuthorship W2518330493A5048321390 @default.
• W2518330493 hasAuthorship W2518330493A5058408501 @default.
• W2518330493 hasBestOaLocation W25183304931 @default.
• W2518330493 hasConcept C126322002 @default.
• W2518330493 hasConcept C127413603 @default.
• W2518330493 hasConcept C2775841333 @default.
• W2518330493 hasConcept C2776572282 @default.
• W2518330493 hasConcept C2777094939 @default.
• W2518330493 hasConcept C2777736543 @default.
• W2518330493 hasConcept C2778402981 @default.
• W2518330493 hasConcept C2779384505 @default.
• W2518330493 hasConcept C2779581417 @default.
• W2518330493 hasConcept C2780645631 @default.
• W2518330493 hasConcept C42219234 @default.
• W2518330493 hasConcept C500558357 @default.
• W2518330493 hasConcept C529278444 @default.
• W2518330493 hasConcept C541997718 @default.
• W2518330493 hasConcept C71924100 @default.
• W2518330493 hasConcept C78519656 @default.
• W2518330493 hasConceptScore W2518330493C126322002 @default.
• W2518330493 hasConceptScore W2518330493C127413603 @default.
• W2518330493 hasConceptScore W2518330493C2775841333 @default.
• W2518330493 hasConceptScore W2518330493C2776572282 @default.
• W2518330493 hasConceptScore W2518330493C2777094939 @default.
• W2518330493 hasConceptScore W2518330493C2777736543 @default.
• W2518330493 hasConceptScore W2518330493C2778402981 @default.
• W2518330493 hasConceptScore W2518330493C2779384505 @default.
• W2518330493 hasConceptScore W2518330493C2779581417 @default.
• W2518330493 hasConceptScore W2518330493C2780645631 @default.
• W2518330493 hasConceptScore W2518330493C42219234 @default.
• W2518330493 hasConceptScore W2518330493C500558357 @default.
• W2518330493 hasConceptScore W2518330493C529278444 @default.
• W2518330493 hasConceptScore W2518330493C541997718 @default.
• W2518330493 hasConceptScore W2518330493C71924100 @default.
• W2518330493 hasConceptScore W2518330493C78519656 @default.
• W2518330493 hasIssue "2" @default.
• W2518330493 hasLocation W25183304931 @default.
• W2518330493 hasLocation W25183304932 @default.
• W2518330493 hasLocation W25183304933 @default.
• W2518330493 hasLocation W25183304934 @default.
• W2518330493 hasLocation W25183304935 @default.
• W2518330493 hasOpenAccess W2518330493 @default.
• W2518330493 hasPrimaryLocation W25183304931 @default.
• W2518330493 hasRelatedWork W1509608683 @default.
• W2518330493 hasRelatedWork W2003741871 @default.
• W2518330493 hasRelatedWork W2022175645 @default.
• W2518330493 hasRelatedWork W205404821 @default.
• W2518330493 hasRelatedWork W2131721740 @default.
• W2518330493 hasRelatedWork W2160454231 @default.

• next